Time to seek further clarity in the molecular analysis of von Willebrand disease?

Emmanuel J. Favaloro

doi:10.1160/TH09-02-0111

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(01): 175-177
DOI: 10.1160/TH09-02-0111

Letters to the Editor

Schattauer GmbH

Time to seek further clarity in the molecular analysis of von Willebrand disease?

Authors

Emmanuel J. Favaloro

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, New South Wales, Australia

Abstract

Full Text

References

References
1 Lester W, Guilliatt A, Grundy P. et al. Is VWF R924Q a benign polymorphism, a marker of a null allele or a factor VIII-binding defect? The debate continues with results from the UKHCDO VWD study. Thromb Haemost 2008; 100: 716-718.
2 Cumming A, Grundy P, Keeney S. et al. the UK Haemophilia Centre Doctors’ Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-641.
3 Goodeve A, Eikenboom J, Castaman G. et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
4 James PD, Paterson AD, Notley C. et al. and Association of Hemophilia Clinic Directors of Canada. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006; 04: 783-792.
5 James PD, Notley C, Hegadorn C. et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109: 145-154.
6 Castaman G, Lethagen S, Federici AB. et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111: 3531-3539.
7 Millar CM, Riddell AF, Brown SA. et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost 2008; 99: 916-924.
8 Favaloro EJ, Bonar R, Kershaw G. et al. (on behalf of the RCPA QAP in Haematology). Reducing errors in identification of von Willebrand disease: The experience of the Royal college of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost 2006; 32: 505-513.
9 Sadler JE, Budde U, Eikenboom JC. et al. Working Party on von Willebrand Disease Classification. Up-date on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 04: 2103-2114.
10 James P, Lillicrap D. The role of molecular genetics in diagnosing von Willebrand disease. Semin Thromb Hemost 2008; 34: 502-508.
11 Othman M, Favaloro EJ. Genetics of type 2B von Willebrand disease: “true 2B”, “tricky 2B”, or “not 2B”. What are the modifiers of the phenotype?. Semin Thromb Hemost 2008; 34: 520-531.
12 Casonato A, Sartorello F, Pontara E. et al. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis. Thromb Haemost 2007; 98: 1182-1187.
13 Website http://www.vwf.group.shef.ac.uk/index.html Last accessed 14th February, 2009.
14 Corrales I, Ramírez L, Altisent C. et al. Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost 2009; 101: 570-576.